127 results
Page 3 of 7
6-K
EX-99.2
mz4qn34 bnnb940w8l81
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
bbmxjgfxvyco2
14 Aug 23
Prospectus supplement
4:42pm
424B3
sg2jlgw6mem6acyezuc
14 Aug 23
Prospectus supplement
4:40pm
6-K
EX-99.1
hy7fnh22
4 Aug 23
XORTX Appoints Chief Financial Officer
5:00pm
POS AM
eeusu7ds0tv8qsvd v0
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm
POS AM
h8z8i pa8
4 Aug 23
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.1
xh42p 9dnmpdy15aypp
29 Jun 23
XORTX Announces Results of Annual and Special Meeting of Shareholders
8:02am
6-K
EX-99.1
s3zyqva1kod9
27 Jun 23
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
2:15pm
6-K
EX-99.1
yu6ut vjvzivxi
6 Jun 23
XORTX Announces PKD Presentation
7:00am
6-K
EX-99.1
8av8vons51pszkh8r
24 May 23
XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
7:00am
6-K
EX-99.2
aus kx0caysiwih
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
6-K
EX-99.1
oxtqj1re2y940yt t8r1
4 May 23
FDA Confirms Eligibility of XORLO™ for Accelerated Approval
7:00am
6-K
EX-99.3
ntok5j8t
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.1
9zsabjg9 s7yds
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.2
ze7 t14ch9qhhnchz
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.1
1kt3s
19 Dec 22
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
8:12am
6-K
EX-99.1
ak0ezh1tu8ot6r1kv0k
8 Dec 22
Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney Expansion
7:00am